LOG IN
SIGN UP
MARKET
ATOS
ATOS
Atossa Therapeutics Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
1.085
-0.005
-0.46%
Opening 10:25 07/01 EDT
OPEN
1.000
PREV CLOSE
1.090
HIGH
1.101
LOW
0.9901
VOLUME
616.97K
TURNOVER
397.25K
52 WEEK HIGH
7.15
52 WEEK LOW
0.8351
MARKET CAP
137.39M
P/E (TTM)
-6.2035
1D
5D
1M
3M
1Y
5Y
BRIEF-Atossa Therapeutics Plans To Complete Required Ongoing Studies And Submit Information Required By FDA By End Of Q3 2022
BRIEF-Atossa Therapeutics Plans To Complete Required Ongoing Studies And Submit Information Required By FDA By End Of Q3 2022
Reuters · 5h ago
Atos CFO to exit; Nathalie Sénéchault to take over
reuters.com · 06/19 08:11
20 Stocks Moving in Wednesday's Pre-Market Session
Gainers Cyren Ltd. (NASDAQ: CYRN) rose 31.1% to $2.32 in pre-market trading after the company entered into an agreement with Content Services Group to sell all equity interests in its legacy secure email gateway business.
Benzinga · 06/08 09:59
BRIEF-Atossa Therapeutics Says On June 1, Submitted An Investigational New Drug To FDA For Atossa's Proprietary Oral (Z)-Endoxifen Capsules
reuters.com · 06/06 18:49
Atossa Files IND to FDA for Oral (Z)-Endoxifen Capsules for Patients With ER+/HER2- Breast Cancer
MT Newswires · 06/06 15:21
Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference
SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious disease...
GlobeNewswire · 05/18 13:30
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 05/14 12:55
Atossa Therapeutics GAAP EPS of -$0.04 beats by $0.02
Atossa Therapeutics press release (NASDAQ:ATOS): Q1 GAAP EPS of -$0.04 beats by $0.02. As of March 31, 2022, the company had cash, cash equivalents and restricted cash of approximately $131,596.
Seekingalpha · 05/09 21:13
No Data
Learn about the latest financial forecast of ATOS. Analyze the recent business situations of Atossa Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 2 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ATOS stock price target is 5.75 with a high estimate of 7.50 and a low estimate of 4.000.
Current 1.020
EPS
Actual
Estimate
-0.05-0.04-0.02-0.01
Institutional Holdings
Institutions: 87
Institutional Holdings: 37.67M
% Owned: 29.75%
Shares Outstanding: 126.62M
TypeInstitutionsShares
Increased
15
1.70M
New
11
552.60K
Decreased
35
4.70M
Sold Out
19
1.05M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.56%
Pharmaceuticals & Medical Research
+0.55%
Key Executives
Chairman/Chief Executive Officer/President/Director
Steven Quay
Chief Financial Officer/General Counsel/Secretary
Kyle Guse
Director
Shu-Chih Chen
Independent Director
Stephen Galli
Independent Director
H. Lawrence Remmel
Independent Director
Richard Steinhart
Independent Director
Gregory Weaver
No Data
No Data
About ATOS
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing medicines for breast cancer, other breast conditions and Covid-19. Its Covid-19 drugs under development, including the AT-H201 program, is for severely ill patients on ventilators, and AT-301 COVID-19 is a nasal spray. Its nasal spray formulation AT-301 is being designed to contain ingredients that can potentially block SARS-CoV-2 viral entry gene proteins in nasal epithelial cells by interfering with spike protein activation by host proteases, by masking receptor binding domains via electrostatic mechanisms, and by providing a generalized mucoadhesive epithelial barrier. AT-H201 program is to develop a therapy to improve lung and function like a chemical vaccine. It is also developing an oral formulation of Endoxifen to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy.
Webull offers kinds of Atossa Therapeutics Inc stock information, including NASDAQ:ATOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATOS stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading ATOS stock methods without spending real money on the virtual paper trading platform.